Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging Targeted Therapies for HER2-Positive Breast Cancer
María F. Mercogliano, Sofía Bruni, Florencia Mauro, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1987-1987
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Matin Chehelgerdi, Fereshteh Behdarvand Dehkordi, Mohammad Chehelgerdi, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 64
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 26
Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions
Rohan Kalyan Rej, Joyeeta Roy, Srinivasa Rao Allu
Cancers (2024) Vol. 16, Iss. 3, pp. 552-552
Open Access | Times Cited: 17
Lighting Up Dual-Aptamer-Based DNA Logic-Gated Series Lamp Probes with Specific Membrane Proteins for Sensitive and Accurate Cancer Cell Identification
Xiaoyu Zhou, Chenghao Yu, Xiaoling Wei, et al.
Analytical Chemistry (2025)
Closed Access | Times Cited: 1
Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance
C. Raman Suri, Babita Pande, Lakkakula Suhasini Sahithi, et al.
Cancer Drug Resistance (2025)
Open Access | Times Cited: 1
Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
Elizabeth S. Rubin, Khine Shan, Shivani Dalal, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1064-1064
Open Access | Times Cited: 12
A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models
Mika K. Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1941-1941
Open Access | Times Cited: 12
Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers
Mika K. Kaneko, Hiroyuki Suzuki, Yukinari Kato
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2024) Vol. 43, Iss. 2, pp. 35-43
Open Access | Times Cited: 11
Emerging paradigms and recent progress in targeting ErbB in cancers
Nicolas Stoup, Maxime Liberelle, Nicolas Lebègue, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 552-576
Open Access | Times Cited: 5
PhyIndBC: Development of a machine learning tool for screening of potential breast cancer inhibitors from phytochemicals
Agneesh Pratim Das, Subhash Mohan Agarwal
Current Plant Biology (2025) Vol. 42, pp. 100435-100435
Open Access
Antitumor Activities of a Humanized Cancer-Specific Anti-HER2 Monoclonal Antibody, humH2Mab-250 in Human Breast Cancer Xenografts
Mika K. Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1079-1079
Open Access
Protein biomarkers in breast cancer: Implication in diagnosis and prognosis
Simpla Mahato, Vivek Tiwari, Seema Seema, et al.
Elsevier eBooks (2025), pp. 163-172
Closed Access
An Electrochemical Fluorescence Dual-Mode Strategy for Her2-Positive Breast Cancer Cell Detection
Qiao Liang, Zhiling Zhang
(2025)
Closed Access
Breast Cancer-the-State-of-the Art in the World and Islamic Development Banks Members Countries (IsDB-MCs)
Ahmed A. M. Elnour
(2025), pp. 169-213
Closed Access
Advancing biliary tract malignancy treatment: emerging frontiers in cell-based therapies
Jian‐Yang Ao, Mingtai Hu, Jinghan Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Two-site synergistic binding strategy for improving adsorption and separation performance of antibodies
Xia Liu, Wenzhuo Dong, Mengqian Jia, et al.
Chinese Chemical Letters (2025), pp. 110991-110991
Closed Access
Evaluation of Lapatinib Tablets Equivalence in the Comparative Dissolution Kinetics Test
З. С. Шпрах, Ya. A. Poskedova, О. Л. Орлова, et al.
Pharmaceutical Chemistry Journal (2025)
Closed Access
Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications
Mahalakshmi Devaraji, Punniyakoti T. Veeraveedu
Cancer Pathogenesis and Therapy (2025)
Open Access
Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment
Swati Saini, Nisha Gulati, Rajendra Awasthi, et al.
Current Drug Delivery (2023) Vol. 21, Iss. 7, pp. 993-1009
Closed Access | Times Cited: 13
Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells
Amalia Kotsifaki, Sousanna Maroulaki, Athanasios Armakolas
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4832-4832
Open Access | Times Cited: 4
Personalized cancer vaccine design using AI-powered technologies
Anant Kumar, Shriniket Dixit, Kathiravan Srinivasan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
Filomena Marino Carvalho
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Biochemical implications of robotic surgery: a new frontier in the operating room
Leila Mokhtari, Fatemeh Hosseinzadeh, Alireza Nourazarian
Journal of Robotic Surgery (2024) Vol. 18, Iss. 1
Closed Access | Times Cited: 3
Discovery of novel HER2 targeting peptide-camptothecin conjugates with effective suppression for selective cancer treatment
Hanyu Wu, Yunxiao Liu, Jiaqi Zhou, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107371-107371
Closed Access | Times Cited: 3
Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer
Chrysanthi Koukoutzeli, Dario Trapani, Liliana Ascione, et al.
Clinical Medicine Insights Oncology (2024) Vol. 18
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top